Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center

Aging Health

Volumn 9, Issue 2, 2013, Pages 229-235

  Givens, Raymond C ^a   Russo, Chris ^a   Green, Philip ^a   Maurer, Mathew S ^a  

^a Columbia College of Physicians and Surgeons ^*  (United States)

Author keywords

African American; amyloidosis; elderly; heart failure; transthyretin

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITRATE; POTASSIUM; WARFARIN;

ADULT; AFRICAN AMERICAN; AFRICAN LATINO; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOMYOPATHY; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; ETHNIC DIFFERENCE; ETHNIC GROUP; FEMALE; HEART AMYLOIDOSIS; HEART EJECTION FRACTION; HEART GRAFT; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LUNG PRESSURE; MAJOR CLINICAL STUDY; MALE; NEGRO; POTASSIUM BLOOD LEVEL; PROTEIN BLOOD LEVEL; SENILE CARDIAC AMYLOIDOSIS;

EID: 84875956829     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/ahe.13.10     Document Type: Article

References (16)

1. Dharmarajan K, Maurer MS. Transthyretin cardiac amyloidoses in older North Americans. J. Am. Geriatr. Soc. 60, 765-774 (2012
2. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 126, 1286-1300 (2012
3. Lai Z, Colon W, Kelly JW. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 35, 6470-6482 (1996
4. Jacobson DR, Pastore R, Pool S et al. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum. Genet. 98, 236-238 (1996
5. Yamashita T, Hamidi Asl K, Yazaki M, Benson MD. A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid 12, 127-130 (2005
6. Jiang X, Buxbaum JN, Kelly JW. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc. Natl Acad. Sci. USA 98, 14943-14948 (2001
7. Buck FS, Koss MN, Sherrod AE, Wu A, Takahashi M. Ethnic distribution of amyloidosis: An autopsy study. Mod. Pathol. 2, 372-377 (1989
8. Dungu J, Sattianayagam PT, Whelan CJ et al. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am. Heart J. 164, 72-79 (2012
9. Jacobson D, Tagoe C, Schwartzbard A, Shah A, Koziol J, Buxbaum J. Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African-American men. Am. J. Cardiol. 108, 440-444 (2011
10. Connors LH, Prokaeva T, Lim A et al. Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am. Heart J. 158, 607-614 (2009
11. Buxbaum J, Alexander A, Koziol J, Tagoe C, Fox E, Kitzman D. Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am. Heart J. 159, 864-870 (2010
12. Ruberg FL, Maurer MS, Judge DP et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS). Am. Heart J. 164, 222-228.e1 (2012
13. Bulawa CE, Connelly S, Devit M et al. Tafamid is, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc. Natl Acad. Sci. USA 109, 9629-9634 (2012
14. de Lartigue J. Tafamidis for transthyretin amyloidosis. Drugs Today 48, 331-337 (2012
15. Castano A, Helmke S, Alvarez J, Delisle S, Maurer MS. Diflunisal for ATTR cardiac amyloidosis. Congest. Heart Fail. 18(6), 315-319 (2012
16. Ackermann EJ, Guo S, Booten S et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 19(Suppl. 1), 43-44 (2012